Duke Street Bio Receives EMA Approval for PARP1 Inhibitor Trial

LONDON, UK, September 24, 2024 – Duke Street Bio Ltd, a biotechnology firm specializing in precision medicine and the development of advanced small molecule cancer therapies, has announced that the European Medicines Agency (EMA) has approved the commencement of a clinical trial for its highly-selective PARP1 inhibitor, DSB2455.

DSB2455 is a promising new treatment that targets cancers with homologous recombination deficiencies (HRD), including those with BRCA mutations. Unlike first-generation non-selective PARP1/2 inhibitors, which have shown limited applicability due to safety concerns, particularly when combined with other treatments like chemotherapy and radiotherapy, DSB2455 focuses exclusively on inhibiting PARP1. This selective approach aims to deliver a significantly improved therapeutic index, marking a notable advancement in precision medicine for cancer treatment.

Preliminary data from preclinical studies reveal that DSB2455 has a strong safety profile and exhibits compelling efficacy, encouraging the transition to clinical trials. The approval from the EMA allows Duke Street Bio to begin testing this innovative therapy in human subjects.

Alan Wise, CEO of Duke Street Bio, expressed his enthusiasm about the approval, stating, "The authorization of the DSB2455 First-in-Human clinical trial by the EMA underscores the therapeutic promise of our approach within the DNA Damage Response (DDR) field. Our mission is to enhance patient outcomes and offer new hope to those battling cancer. We believe that DSB2455 can provide superior efficacy and tolerability compared to first-generation PARP inhibitors, addressing significant unmet medical needs in various patient populations."

Duke Street Bio is committed to advancing the field of cancer treatment by developing therapies that reprogram tumor biology, targeting the genetic and immune pathways responsible for cancer growth. Their groundbreaking research and innovative treatments aim to improve the lives of patients diagnosed with cancer.